Los puntos clave no están disponibles para este artículo en este momento.
Lucitanib had modest antitumor activity and significant hypertension-related toxicity in patients with HR + /HER2 - MBC. Although based on small sample sizes, exploratory biomarker analyses suggested that patients with high FGFR1 amplification or expression might derive greater benefit.
Hui et al. (Wed,) studied this question.